Ninth Circuit affirms Elizabeth Holmes conviction in $452M Theranos fraud case

The Ninth Circuit shut down Elizabeth Holmes's appeal, affirming fraud convictions and a $452 million restitution order for Theranos investors and business partners.

One of Silicon Valley's biggest investor fraud cases has nearly run its course. The December 22 ruling means Elizabeth Holmes and her former business partner are heading to prison, and victims are getting their money back.

Holmes is facing 135 months behind bars. Balwani got 155 months. Both were convicted on multiple wire fraud counts for lying to investors about what their blood-testing company could actually do.

Here's what happened. Between 2010 and 2015, Holmes and Balwani told investors they had developed revolutionary technology that could run hundreds of accurate blood tests from just a finger prick. The pitch was compelling. No more needles in your arm. Fast results. Affordable testing.

The problem? The technology never worked.

Former employees testified that the Edison device, Theranos's proprietary blood-testing machine, kept failing quality control checks. Out of 300 tests the company developed, only 12 ever ran on the Edison. Other general chemistry tests ran on third-party commercial machines that Theranos bought from other companies and modified.

But investors never knew this. When potential backers visited for demonstrations, Holmes and Balwani would put them in a room with an Edison device. The visitors thought they were watching their blood samples being tested in real time. Actually, the device was running a fake protocol while their samples were being tested on third-party equipment in another room.

The financial picture was just as fraudulent. Theranos had zero revenue in 2012 and 2013. The company lost $57 million in 2012 and $92 million in 2013. In 2015, total income was less than $2 million. Yet investors were shown projections claiming Theranos would make $230 million in profit by the end of 2015.

Holmes also fabricated endorsements from pharmaceutical companies. She personally put Pfizer's logo on reports about Theranos technology, even though Pfizer never validated the device. Representatives from Pfizer and other drug companies testified they never authorized use of their logos and never independently verified anything Theranos claimed.

The military angle was equally misleading. Multiple investors testified that Holmes and Balwani led them to believe Theranos devices were being used by the military on medevac helicopters and battlefields. General James Mattis testified that never happened. The device was never deployed in combat, never installed on military helicopters, never used to treat servicemembers on the battlefield.

Six investors bought shares in 2013 and 2014 based on these misrepresentations. The appeals court found that 12 investors total qualified as victims under federal restitution laws.

Holmes and Balwani tried multiple arguments to overturn their convictions. They challenged expert testimony, evidence rulings, and constitutional issues. The appeals court rejected everything. Even where trial errors might have occurred, the overwhelming evidence of fraud made those errors harmless.

On restitution, the court confirmed victims get back every dollar they put in. Why the full amount? Because after the fraud came out in late 2015, Theranos shares became worthless and illiquid. Investors couldn't sell them to anyone. One investor testified there was never any legitimate opportunity to sell once negative publicity hit.

This is the final decision from the federal appeals court. For practical purposes, this chapter is closed.